A recent BMJ editorial, Malnutrition with use of GLP-1 agonists is an underestimated real world harm, highlights how these therapies can cause unintended nutritional consequences that remain poorly recognised in practice (BMJ 2025)
The mechanism is not 'you eat collagen, you become collagen' it is that specific di- and tripeptides (prolyl-hydroxyproline) survive digestion, reach the dermis and tendon, and act as signalling fragments
Other procedures are described below
Caution is required in patients with a history of pancreatitis, as GLP-1 receptor agonists have been associated with acute pancreatitis
BPC-157 has demonstrated efficacy in repairing transected tendons and ligaments, healing muscle injuries, accelerating bone fracture recovery, and treating gastrointestinal ulcers and inflammatory bowel conditions
Strategic application methods can improve penetration and results